



A WNS COMPANY

Procedure Codes

2023
BayCarePlus
v7
Effective 10/27/2023

NOTE: Yellow highlight denotes new procedure code(s) for 2023.

DIAGNOSTIC RADIOLOGY

MRA

Magnetic resonance angiography, head; without contrast material(s)	70544
Magnetic resonance angiography, head; with contrast material(s)	70545
Magnetic resonance angiography, head; without contrast material(s) followed by contrast material(s) and further sequences	70546
Magnetic resonance angiography, neck; without contrast material(s)	70547
Magnetic resonance angiography, neck; with contrast material(s)	70548
Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences	70549
Magnetic resonance angiography, chest (excluding myocardium), with or without contrast material(s)	71555
Magnetic resonance angiography with contrast, chest (excluding myocardium)	C8909
Magnetic resonance angiography without contrast, chest (excluding myocardium)	C8910
Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)	C8911
Magnetic resonance angiography, spinal canal and contents, with or without contrast material(s)	72159
Magnetic resonance angiography with contrast, spinal canal and contents	C8931
Magnetic resonance angiography without contrast, spinal canal and contents	C8932
Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents	C8933
Magnetic resonance angiography, pelvis, with or without contrast material(s)	72198
Magnetic resonance angiography with contrast, pelvis	C8918
Magnetic resonance angiography without contrast, pelvis	C8919
Magnetic resonance angiography without contrast followed by with contrast, pelvis	C8920
Magnetic resonance angiography, upper extremity, with or without contrast material(s)	73225
Magnetic resonance angiography with contrast, upper extremity	C8934
Magnetic resonance angiography without contrast, upper extremity	C8935
Magnetic resonance angiography without contrast followed by with contrast, upper extremity	C8936
Magnetic resonance angiography, lower extremity, with or without contrast material(s)	73725
Magnetic resonance angiography with contrast, lower extremity	C8912
Magnetic resonance angiography without contrast, lower extremity	C8913
Magnetic resonance angiography without contrast followed by with contrast, lower extremity	C8914
Magnetic resonance angiography, abdomen, with or without contrast material(s)	74185
Magnetic resonance angiography with contrast, abdomen	C8900
Magnetic resonance angiography without contrast, abdomen	C8901
Magnetic resonance angiography without contrast followed by with contrast, abdomen	C8902

MRI	
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	70336
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)	70540
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)	70542
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences	70543
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	70551
Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material	70552
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences	70553
Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration	70554
Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, requiring physician or psychologist administration of entire neurofunctional testing	70555
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s)	71550
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); with contrast material(s)	71551
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s), followed by contrast material(s) and further sequences	71552
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material	72141
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; with contrast material(s)	72142
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical	72156
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic without contrast material	72146
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic with contrast material(s)	72147
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic	72157
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material	72148
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; with contrast material(s)	72149
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar	72158
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)	72195
Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s)	72196
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences	72197
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s)	73218
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; with contrast material(s)	73219
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences	73220
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)	73221
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; with contrast material(s)	73222
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences	73223
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)	73718
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; with contrast material(s)	73719

MRI (cont)

Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences	73720
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material	73721
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; with contrast material(s)	73722
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences	73723
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)	74181
Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)	74182
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences	74183
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	74712
Cardiac magnetic resonance imaging for morphology and function without contrast material;	75557
Cardiac magnetic resonance imaging for morphology and function without contrast material; with stress imaging	75559
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences;	75561
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging	75563
Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	C9762
Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	C9763
Magnetic resonance imaging, breast, without contrast material; unilateral	77046
Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral	77048
Magnetic resonance imaging with contrast, breast; unilateral	C8903
Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral	C8905
Magnetic resonance imaging, breast, without contrast material; bilateral	77047
Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral	77049
Magnetic resonance imaging with contrast, breast; bilateral	C8906
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral	C8908
Magnetic resonance (eg, proton) imaging, bone marrow blood supply	77084
Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	C9791

Cardiac Nuclear Medicine

Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	78451
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or reinjection	78452
Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	78453
Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or reinjection	78454
Myocardial Imaging, infarct avid, planar; qualitative or quantitative	78466
Myocardial Imaging with ejection fraction, first pass technique	78468
Myocardial Imaging, tomographic SPECT with or without quantification	78469
Cardiac Blood Pool Imaging, gated equilibrium; planar, single study Rest or Stress, wall motion study + ejection fraction, w/ or w/o quantitative processing	78472
Cardiac Blood Pooling Imaging, multiple studies, wall motion study plus ejection fraction, at rest or stress, w/ or w/o additional quantification	78473

Cardiac Nuclear Medicine (cont)

Cardiac Blood Pool Imaging, planar, first pass technique, single study, rest or stress, wall motion study + ejection fraction, w/ or w/o quantification	78481
Cardiac Blood Pool Imaging, multiple studies, rest and stress, wall motion study + ejection fraction, w/ or w/o quantification	78483
Cardiac Blood Pool Imaging, gated equilibrium, SPECT; planar, single study rest or stress, wall motion study + ejection fraction, w/ or w/o quantitative processing	78494

PET

Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed, single study;	78459
Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed, single study; with concurrently acquired computed tomography transmission scan	78429
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(S) and/or ejection fraction(s), when performed; single study at rest or stress (exercise or pharmacologic)	78491
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(s) and/or ejection fraction(s), when performed; single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	78430
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(S) and/or ejection fraction(s), when performed; multiple studies at rest or and stress (exercise or pharmacologic)	78492
Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion(s) and/or ejection fraction(s), when performed; multiple studies, at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan	78431
Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed), dual radiotracer (eg, myocardial viability);	78432
Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion(s) and/or ejection fraction(s), when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan	78433
Brain imaging, positron emission tomography (PET); metabolic evaluation	78608
Brain imaging, positron emission tomography (PET); perfusion evaluation	78609
Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)	78811
Positron emission tomography (PET) imaging; skull base to mid-thigh	78812
Positron emission tomography (PET) imaging; whole body	78813
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)	78814
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	78815
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body	78816
PET imaging whole body; melanoma for noncovered indications	G0219
PET imaging, any site, not otherwise specified	G0235
PET imaging, full and partial-ring PET scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes)	G0252

RADIATION THERAPY**2D3D**

Radiation treatment delivery, superficial and/or ortho voltage, per day	77401
Radiation treatment delivery, >1 MeV; simple	77402
Radiation treatment delivery, >1 MeV; intermediate	77407
Radiation treatment delivery, >1 MeV; complex	77412
Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5MeV	G6003
Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10MeV	G6004

2D3D (cont)

Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19MeV	G6005
Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20MeV or greater	G6006
Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5MeV	G6007
Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10MeV	G6008
Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19MeV	G6009
Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20MeV or greater	G6010
Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5MeV	G6011
Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10MeV	G6012
Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19MeV	G6013
Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20MeV or greater	G6014

Brachytherapy

Intraoperative radiation treatment delivery, x-ray, single treatment session	77424
Intraoperative radiation treatment delivery, electrons, single treatment session	77425
Infusion or instillation of radioelement solution (includes 3 months follow-up care)	77750
Intracavitary radiation source application; simple	77761
Intracavitary radiation source application; intermediate	77762
Intracavitary radiation source application; complex	77763
Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel	77767
Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions	77768
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel	77770
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels	77771
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels	77772
Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed	77778
Surface application of low dose rate radionuclide source	77789
High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	0394T
High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	0395T
Low dose rate (LDR) prostate brachytherapy services, composite rate	G0458

IMRT

Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple	77385
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	77386
Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session	G6015
Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session	G6016

Neutron Therapy

High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and / or wedge, and / /or compensator(s)	77423
--	-------

Proton Beam	
Proton treatment delivery; simple, without compensation	77520
Proton treatment delivery; simple, with compensation	77522
Proton treatment delivery; intermediate	77523
Proton treatment delivery; complex	77525

Stereotactic Radiosurgery	
Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	32701
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion	61796
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion	61798
Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion	63620
Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based	77371
Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based	77372
Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	77373
Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session, or first session of fractionated treatment	G0339
Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment	G0340

MEDICAL ONCOLOGY

NOTE: Procedure codes indicated for treatment of medical oncology diagnoses only.

NOTE: All medical oncology drugs must be submitted for review, including drugs with codes not otherwise specified.

HCPCS	
LUTETIUM LU 177, DOTATATE, THERAPEUTIC, 1 MILLICURIE	A9513
INDIUM IN-111 IBRITUMOMAB TIUXETAN, DIAGNOSTIC, PER STUDY DOSE, UP TO 5 MILLICURIES	A9542
YTTRIUM Y-90 IBRITUMOMAB TIUXETAN, THERAPEUTIC, PER TREATMENT DOSE, UP TO 40 MILLICURIES	A9543
IODINE I-131, IOBENGUANE, 1 MILLICURIE	A9590
RADIUM RA-223 DICHLORIDE, THERAPEUTIC, PER MICROCURIE	A9606
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, THERAPEUTIC, 1 MILLICURIE	A9607
RADIOPHARMACEUTICAL, THERAPEUTIC, NOT OTHERWISE CLASSIFIED	A9699
Indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.	C9155
INJECTION, BEVACIZUMAB, 0.25 MG	C9257
INJECTION, GLUCARPIDASE, 10 UNITS	C9293
UNCLASSIFIED DRUGS OR BIOLOGICALS	C9399
INJECTION, ALEMTUZUMAB, 1 MG	J0202
INJECTION, AMIFOSTINE, 500 MG	J0207
INJECTION, BUSULFAN, 1 MG	J0594
INJECTION, LEUCOVORIN CALCIUM, PER 50 MG	J0640
INJECTION, LEVOLEUCOVORIN, NOT OTHERWISE SPECIFIED, 0.5 MG	J0641
INJECTION, LEVOLEUCOVORIN (KHAPZORY), 0.5 MG	J0642
INJECTION, DARBEPOETIN ALFA, 1 MICROGRAM (NON-ESRD USE)	J0881
INJECTION, EPOETIN ALFA, (FOR NON-ESRD USE), 1000 UNITS	J0885
INJECTIN, EPOETIN BETA, 1 MICROGRAM, (FOR NON ESRD USE)	J0888
Injection, decitabine (sun pharma) not therapeutically equivalent to j0894, 1 mg	J0893
INJECTION, DECITABINE, 1 MG	J0894
INJECTION, DENOSUMAB, 1 MG	J0897
INJECTION, FILGRASTIM (G-CSF), EXCLUDES BIOSIMILARS, 1 MICROGRAM	J1442
INJECTION, TBO-FILGRASTIM, 1 MICROGRAM	J1447
INJECTION, TRILACICLIB, 1 MG	J1448
Injection, eflapegrastim-xnst, 0.1 mg	J1449
INJECTION, FOSNETUPITANT 235 MG AND PALONOSETRON 0.25 MG	J1454
Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg	J1456
INJECTION, IMMUNE GLOBULIN, (GAMMAPLEX), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID), 500 MG	J1557
INJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID), 500 MG	J1561
INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED (E.G. POWDER), NOT OTHERWISE SPECIFIED, 500 MG	J1566

HCPCS (cont)

INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID), 500 MG	J1569
INJECTION, IMMUNE GLOBULIN, (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID), 500 MG	J1572
Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	J1576
INJECTION, LANREOTIDE, 1 MG	J1930
INJECTION, LANREOTIDE, (CIPLA), 1 MG	J1932
INJECTION, LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), PER 3.75 MG	J1950
LEUPROLIDE INJECTABLE, CAMCEVI, 1 MG	J1952
INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG	J2353
INJECTION, OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCG	J2354
INJECTION, PAMIDRONATE DISODIUM, PER 30 MG	J2430
INJECTION, PALONOSETRON HCL, 25 MCG	J2469
INJECTION, PEGFILGRASTIM, EXCLUDES BIOSIMILAR, 0.5 MG	J2506
INJECTION, PLERIXAFOR, 1 MG	J2562
INJECTION, ROMIPLOSTIM, 10 MICROGRAMS	J2796
INJECTION, ROLAPITANT, 0.5 MG	J2797
INJECTION, SARGRAMOSTIM (GM-CSF), 50 MCG	J2820
INJECTION, SILTUXIMAB, 10 MG	J2860
INJECTION, TOCILIZUMAB, 1 MG	J3262
INJECTION, TRIPTORELIN PAMOATE, 3.75 MG	J3315
INJECTION, TRIPTORELIN, EXTENDED-RELEASE, 3.75 MG	J3316
INJECTION, VEDOLIZUMAB, 1 MG	J3380
INJECTION, ZOLEDRONIC ACID, 1 MG	J3489
UNCLASSIFIED BIOLOGICS	J3590
LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, EQUINE, PARENTERAL, 250 MG	J7504
LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, RABBIT, PARENTERAL, 25 MG	J7511
SIROLIMUS, ORAL, 1 MG	J7520
EVEROLIMUS, ORAL, 0.25 MG	J7527
BUSULFAN; ORAL, 2 MG	J8510
CAPECITABINE, ORAL, 150 MG	J8520
CAPECITABINE, ORAL, 500 MG	J8521
CYCLOPHOSPHAMIDE; ORAL, 25 MG	J8530
ETOPOSIDE; ORAL, 50 MG	J8560
ANTIEMETIC DRUG, ORAL, NOT OTHERWISE SPECIFIED	J8597
METHOTREXATE; ORAL, 2.5 MG	J8610
TEMOZOLOMIDE, ORAL, 5 MG	J8700
TOPOTECAN, ORAL, 0.25 MG	J8705
PRESCRIPTION DRUG, ORAL, CHEMOTHERAPEUTIC, NOS	J8999
INJECTION, DOXORUBICIN HYDROCHLORIDE, 10 MG	J9000
INJECTION, ALDESLEUKIN, PER SINGLE USE VIAL	J9015
INJECTION, ARSENIC TRIOXIDE, 1 MG	J9017
INJECTION, ASPARAGINASE (ERWINAZE), 1,000 IU	J9019
INJECTION, ASPARAGINASE, RECOMBINANT, (RYLAZE), 0.1 MG	J9021
INJECTION, ATEZOLIZUMAB, 10 MG	J9022
INJECTION, AVELUMAB, 10 MG	J9023
INJECTION, AZACITIDINE, 1 MG	J9025
INJECTION, CLOFARABINE, 1 MG	J9027
Injection, nadofaragene firadenovec-vncg, per therapeutic dose	J9029
BCG LIVE INTRAVESICAL INSTILLATION, 1 MG	J9030
INJECTION, BELINOSTAT, 10 MG	J9032
INJECTION, BENDAMUSTINE HCL, 1 MG	J9033
INJECTION, BENDAMUSTINE HCL (BENDEKA), 1 MG	J9034
INJECTION, BEVACIZUMAB, 10 MG	J9035
INJECTION, BENDAMUSTINE HYDROCHLORIDE, (BELRAPZO), 1 MG	J9036
INJECTION, BELANTAMAB MAFODONTIN-BLMF, 0.5 MG	J9037
INJECTION, BLINATUMOMAB, 1 MICROGRAM	J9039
INJECTION, BLEOMYCIN SULFATE, 15 UNITS	J9040
INJECTION, BORTEZOMIB (VELCADE), 0.1 MG	J9041
INJECTION, BRENTUXIMAB VEDOTIN, 1 MG	J9042
INJECTION, CABAZITAXEL, 1 MG	J9043
INJECTION, CARBOPLATIN, 50 MG	J9045
Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to J9041, 0.1 mg	J9046
INJECTION, CARFILZOMIB, 1 MG	J9047

HCPCS (cont)

Injection, bortezomib (fresenius kabi), not therapeutically equivalent to J9041, 0.1 mg	J9048
Injection, bortezomib (hospira), not therapeutically equivalent to J9041, 0.1 mg	J9049
INJECTION, CARMUSTINE, 100 MG	J9050
Indicated for the treatment of adult patients with multiple myeloma and the treatment of adult patients with mantle cell lymphoma.	J9051
INJECTION, CETUXIMAB, 10 MG	J9055
Injection, bendamustine hydrochloride (vivimusta), 1 mg	J9056
INJECTION, COPANLISIB, 1 MG	J9057
Injection, bendamustine hydrochloride (apotex), 1 mg	J9058
Injection, bendamustine hydrochloride (baxter), 1 mg	J9059
INJECTION, CISPLATIN, POWDER OR SOLUTION, 10 MG	J9060
INJECTION, AMIVANTAMAB-VMJW, 2 MG	J9061
Injection, mirvetuximab soravtansine-gynx, 1 mg	J9063
Indicated for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.	J9064
INJECTION, CLADRIBINE, PER 1 MG	J9065
CYCLOPHOSPHAMIDE, 100 MG	J9070
INJECTION, CYCLOPHOSPHAMIDE, (AUROMEDICS), 5 MG	J9071
INJECTION, CYTARABINE, 100 MG	J9100
INJECTION, CALASPARGASE PEGOL-MKNL, 10 UNITS	J9118
INJECTION, CEMIPIMAB-RWLC, 1 MG	J9119
INJECTION, DACTINOMYCIN, 0.5 MG	J9120
DACARBAZINE, 100 MG	J9130
INJECTION, DARATUMUMAB, 10 MG AND HYALURONIDASE-FIHJ	J9144
INJECTION, DARATUMUMAB, 10 MG	J9145
INJECTION, DAUNORUBICIN, 10 MG	J9150
INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE	J9153
INJECTION, DEGARELIX, 1 MG	J9155
INJECTION, DOCETAXEL, 1 MG	J9171
INJECTION, DURVALUMAB, 10 MG	J9173
INJECTION, ELLIOTT'S B SOLUTION, 1 ML	J9175
INJECTION, ELOTUZUMAB, 1 MG	J9176
INJECTION, ENFORTUMAB VEDOTIN-EJFV, 0.25 MG	J9177
INJECTION, EPIRUBICIN HCL, 2 MG	J9178
INJECTION, ERIBULIN MESYLATE, 0.1 MG	J9179
INJECTION, ETOPOSIDE, 10 MG	J9181
INJECTION, FLUDARABINE PHOSPHATE, 50 MG	J9185
INJECTION, FLUOROURACIL, 500 MG	J9190
Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg	J9196
INJECTION, GEMCITABINE HYDROCHLORIDE, (INFUGEM), 100 MG	J9198
INJECTION, FLOXURIDINE, 500 MG	J9200
INJECTION, GEMCITABINE HYDROCHLORIDE, 200 MG	J9201
GOSERELIN ACETATE IMPLANT, PER 3.6 MG	J9202
INJECTION, GEMTUMAB OZOGAMICIN, 0.1 MG	J9203
INJECTION, MOGAMULIZUMAB-KPKC, 1 MG	J9204
INJECTION, IRINOTECAN LIPOSOME, 1 MG	J9205
INJECTION, IRINOTECAN, 20 MG	J9206
INJECTION, IXABEPILONE, 1 MG	J9207
INJECTION, IFOSFAMIDE, 1 GRAM	J9208
INJECTION, MESNA, 200 MG	J9209
INJECTION, EMAPALUMAB-LZSG, 1 MG	J9210
INJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG	J9211
INJECTION, INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS	J9214
INJECTION, INTERFERON, ALFA-N3, (HUMAN LEUKOCYTE DERIVED), 250,000 IU	J9215
LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG	J9217
LEUPROLIDE ACETATE, PER 1 MG	J9218
INJECTION, LURBINECTEDIN, 0.1 MG	J9223
HISTRELIN IMPLANT (VANTAS), 50 MG	J9225
HISTRELIN IMPLANT (SUPPRELIN LA), 50 MG	J9226
INJECTION, ISATUXIMAB-IRFC, 10 MG	J9227
INJECTION, IPIILIMUMAB, 1 MG	J9228
INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG	J9229
INJECTION, MECHLORETHAMINE HYDROCHLORIDE, (NITROGEN MUSTARD), 10 MG	J9230
INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG	J9245
INJECTION, MELPHALAN (EVOMELA), 1 MG	J9246
INJECTION, MELPHALAN FLUFENAMIDE, 1 MG	J9247
METHOTREXATE SODIUM, 5 MG	J9250
Injection, paclitaxel protein-bound particles (american reagent) not therapeutically equivalent to J9264, 1 mg	J9259

HCPCS (cont)

METHOTREXATE SODIUM, 50 MG	J9260
INJECTION, NELARABINE, 50 MG	J9261
INJECTION, OMACETAXINE MEPESUCCINATE, 0.01 MG	J9262
INJECTION, OXALIPLATIN, 0.5 MG	J9263
INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG	J9264
INJECTION, PEGASPARGASE, PER SINGLE DOSE VIAL	J9266
INJECTION, PACLITAXEL, 1 MG	J9267
INJECTION, PENTOSTATIN, 10 MG	J9268
INJECTION, TAGRAXOFUSP-ERZS, 10 MCG	J9269
INJECTION, PEMBROLIZUMAB, 1 MG	J9271
INJECTION, DOSTARLIMAB-GXLY, 10 MG	J9272
INJECTION, TISOTUMAB VEDOTIN-TFTV, 1 MG	J9273
INJECTION, TEBENTAFUSP-TEBN, 1 MICROGRAM	J9274
INJECTION, MITOMYCIN, 5 MG	J9280
MITOMYCIN PYELOALYCEAL INSTILLATION, 1 MG	J9281
INJECTION, OLARATUMAB, 10 MG	J9285
INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG	J9293
Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg	J9294
INJECTION, NECITUMUMAB, 1 MG	J9295
Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg	J9296
Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg	J9297
INJECTION, NIVOLUMAB AND RELATLIMAB-RMBW, 3 MG/1 MG	J9298
INJECTION, NIVOLUMAB, 1 MG	J9299
INJECTION, OBINUTUZUMAB, 10 MG	J9301
INJECTION, OFATUMUMAB, 10 MG	J9302
INJECTION, PANITUMUMAB, 10 MG	J9303
INJECTION, PEMETREXED (PEMFEXY), 10 MG	J9304
INJECTION, PEMETREXED, 10 MG	J9305
INJECTION, PERTUZUMAB, 1 MG	J9306
INJECTION, PRALATREXATE, 1 MG	J9307
INJECTION, RAMUCIRUMAB, 5 MG	J9308
INJECTION, POLATUZUMAB VEDOTIN-PLIQ, 1 MG	J9309
INJECTION, RITUXIMAB 10 MG AND HYALURONIDASE	J9311
INJECTION, RITUXIMAB, 10 MG	J9312
INJECTION, MOXETUMOMAB PASUDOTOX-TDFK, 0.01 MG	J9313
Injection, pemetrexed (teva) not therapeutically equivalent to j9305, 10 mg	J9314
INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PER 10 MF	J9316
INJECTION, SACITUZUMAB GOVITECAN-HZIY, 2.5 MG	J9317
INJECTION, ROMIDEPSIN, NON-LYOPHILIZED, 0.1 MG	J9318
INJECTION, ROMIDEPSIN, LYOPHILIZED, 0.1 MG	J9319
INJECTION, STREPTOZOCIN, 1 GRAM	J9320
Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg	J9322
Injection, pemetrexed ditromethamine, 10 mg	J9323
INJECTION, TALIMOGENE LAHERPAREPVEC, 1 MILLION PLAQUE FORMING UNITS (PFU)	J9325
INJECTION, TEMOZOLOMIDE, 1 MG	J9328
INJECTION, TEMSIROLIMUS, 1 MG	J9330
INJECTION, SIROLIMUS PROTEIN-BOUND PARTICLES, 1 MG	J9331
INJECTION, THIOTEPA, 15 MG	J9340
Indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).	J9345
Injection, tremelimumab-actl, 1 mg	J9347
INJECTION, NAXITAMAB-GQGK, 1 MG	J9348
INJECTION, TAFASITAMAB-CXIX, 2 MG	J9349
Injection, mosunetuzumab-axgb, 1 mg	J9350
INJECTION, TOPOTECAN, 0.1 MG	J9351
INJECTION, TRABECTEDIN, 0.1 MG	J9352
INJECTION, MARGETUXIMAB-CMKB, 5 MG	J9353
INJECTION, ADO-TRASTUZUMAB EMTANSINE, 1 MG	J9354
INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG	J9355
INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK	J9356
INJECTION, VALRUBICIN, INTRAVESICAL, 200 MG	J9357
INJECTION, FAM-TRASTUZUMAB DERUXTECAN-NXKI, 1 MG	J9358
INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG	J9359
INJECTION, VINBLASTINE SULFATE, 1 MG	J9360
VINCRISTINE SULFATE, 1 MG	J9370
INJECTION, VINCRISTINE SULFATE LIPOSOME, 1 MG	J9371
Injection, teclistamab-cqyv, 0.5 mg	J9380
INJECTION, VINOURELBINE TARTRATE, 10 MG	J9390

HCPCS (cont)

Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg	J9393
Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg	J9394
INJECTION, FULVESTRANT, 25 MG	J9395
INJECTION, ZIV-AFLIBERCEPT, 1 MG	J9400
INJECTION, PORFIMER SODIUM, 75 MG	J9600
NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS	J9999
INJECTION, TENIPOSIDE, 50 MG	Q2017
AXICABTAGENE CILOLEUCEL , UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION	Q2041
TISAGENLECLEUCEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE	Q2042
SIPULEUCEL-T, MINIMUM OF 50 MILLION AUTOLOGOUS CD54+ CELLS ACTIVATED WITH PAP-GM-CSF, INCLUDING LEUKAPHERESIS AND ALL OTHER PREPARATORY PROCEDURES, PER INFUSION	Q2043
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, IMPORTED LIPODOX, 10 MG	Q2049
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10MG	Q2050
BREXUCABTAGENE AUTOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE	Q2053
LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE	Q2054
IDECABTAGENE VICLEUCEL, UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE	Q2055
CILTACABTAGENE AUTOLEUCEL, UP TO 100 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE	Q2056
INJECTION, FILGRASTIM (G-CSF), BIOSIMILAR, 1 MICROGRAM	Q5101
INJECTION, EPOETIN ALFA, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS	Q5106
INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG	Q5107
INJECTION, PEGFILGRASTIM-JMDB, BIOSIMILAR, (FULPHILA), 0.5 MG	Q5108
INJECTION, FILGRASTIM-AAFI, BIOSIMILAR, (NIVESTYM), 1 MICROGRAM	Q5110
INJECTION, PEGFILGRASTIM-CBQV, BIOSIMILAR, (UDENYCA), 0.5 MG	Q5111
INJECTION, TRASTUZUMAB-DTTB, BIOSIMILAR, (ONTRUZANT), 10 MG	Q5112
INJECTION, TRASTUZUMAB-PKRB, BIOSIMILAR, (HERZUMA), 10 MG	Q5113
INJECTION, TRASTUZUMAB-DKST, BIOSIMILAR, (OGIVRI), 10 MG	Q5114
INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, 10 MG	Q5115
INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG	Q5116
INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG	Q5117
INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG	Q5118
INJECTION, RITUXIMAB-PVVR, BIOSIMILAR, (RUXIENCE), 10 MG	Q5119
INJECTION, PEGFILGRASTIM-BMEZ, BIOSIMILAR, (ZIEXTENZO), 0.5 MG	Q5120
INJECTION, PEGFILGRASTIM-APGF, BIOSIMILAR, (NYVEPRIA), 0.5 MG	Q5122
INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG	Q5123
INJECTION, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM	Q5125
Injection, bevacizumab-maly, biosimilar, (alymys), 10 mg	Q5126
Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	Q5127
Injection, bevacizumab-adcd (vezzelma), biosimilar, 10 mg	Q5129
Injection, pegfilgrastim-pbbk (fynetra), biosimilar, 0.5 mg	Q5130
LOMUSTINE, ORAL, 10MG	S0178